In 2023, research on mice and rats suggested semaglutide — the powerful ingredient behind Wegovy and Ozempic — could raise ...

semaglutide (the active ingredient in Rybelsus) caused thyroid tumors in mice and rats. Animal studies don’t always predict what will happen in people. And no cases of thyroid cancer have been ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

GLP-1RAs were not associated with an increased risk for thyroid cancer relative to DPP-4 inhibitor use among an international cohort.

The type 2 diabetes medication, generically known as semaglutide, has received unprecedented ... for conditions ranging from heart disease to cancer to neurodegenerative diseases.

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

In 2023, research on mice and rats suggested semaglutide — the powerful ingredient behind Wegovy and Ozempic — could raise the risk of one type of thyroid cancer: medullary thyroid cancer (MTC).